Scholfield D W, Sadozai Z, Ghali C, Sumathi V, Douis H, Gaston L, Grimer R J, Jeys L
Royal Orthopaedic Hospital, Birmingham, UK.
Bone Joint J. 2017 Mar;99-B(3):409-416. doi: 10.1302/0301-620X.99B3.38050.
The aim of this study was to identify any progression between benign osteofibrous dysplasia (OFD), OFD-like adamantinoma and malignant adamantinoma, and to investigate the rates of local recurrence, metastases and survival, in order to develop treatment algorithms for each.
A single institution retrospective review of all patients presenting with OFD, OFD-like adamantinoma and adamantinoma between 1973 and 2012 was undertaken. Complete data were available for 73 patients (42 with OFD; ten with an OFD-like adamantinoma and 21 with an adamantinoma). The mean follow-up was 10.3 years (3 to 25) for OFD, 9.2 years (3.0 to 26.3) for OFD-like and 11.6 years (0.25 to 33) for adamantinoma.
The mean age at diagnosis for OFD was 13.5 years (1 to 49), 10.5 years (6 to 28) for OFD-like and 34 years (14 to 86) for adamantinoma. A total of 24 of the 42 patients with OFD (57%) have not required any treatment and have been managed with observation. A total of 18 of the 42 patients with OFD underwent surgery, 13 with curettage and five with resection. In all, three patients developed recurrence following curettage (23%) but none following resection. All these patients were cured with further limited surgery. A total of six patients initially diagnosed with OFD were subsequently found to have OFD-like adamantinoma. Of the ten patients initially diagnosed with OFD-like adamantinoma, three (30%) were managed with observation alone and seven underwent surgery, two with curettage and five with resection. Local recurrence arose in two patients, one each after curettage and resection. No patients with either OFD or an OFD-like adamantinoma developed metastases or had progression to adamantinoma. All patients with an adamantinoma were treated by surgery, three with curettage, six with amputation and 12 with excision. In all, two of the three treated with curettage developed local recurrence, requiring further surgery. Late development of both local recurrence and metastases led to a ten year disease specific survival of 93% which had dropped to 39% by 20 years.
We found no evidence of progression from OFD to adamantinoma. Conservative management with observation or curettage is often successful for patients with OFD and OFD-like adamantinoma. Resection with clear margins is required for patients with adamantinoma. Late tumour recurrence is not uncommon in adamantinoma and prolonged follow-up should be considered. Cite this article: 2017;99-B:409-16.
本研究旨在确定良性骨纤维结构不良(OFD)、类OFD型釉质细胞瘤和恶性釉质细胞瘤之间是否存在进展情况,并调查局部复发率、转移率和生存率,以便为每种情况制定治疗方案。
对1973年至2012年间所有出现OFD、类OFD型釉质细胞瘤和釉质细胞瘤的患者进行单机构回顾性研究。73例患者有完整数据(42例OFD;10例类OFD型釉质细胞瘤和21例釉质细胞瘤)。OFD患者的平均随访时间为10.3年(3至25年),类OFD型患者为9.2年(3.0至26.3年),釉质细胞瘤患者为11.6年(0.25至33年)。
OFD诊断时的平均年龄为13.5岁(1至49岁),类OFD型为10.5岁(6至28岁),釉质细胞瘤为34岁(14至86岁)。42例OFD患者中共有24例(57%)无需任何治疗,采用观察处理。42例OFD患者中有18例接受了手术,13例行刮除术,5例行切除术。总体而言,3例患者刮除术后复发(23%),但切除术后无复发。所有这些患者通过进一步的有限手术治愈。最初诊断为OFD的6例患者随后被发现患有类OFD型釉质细胞瘤。最初诊断为类OFD型釉质细胞瘤的10例患者中,3例(30%)仅采用观察处理,7例接受了手术,2例行刮除术,5例行切除术。2例患者出现局部复发,刮除术和切除术后各1例。OFD或类OFD型釉质细胞瘤患者均未发生转移或进展为釉质细胞瘤。所有釉质细胞瘤患者均接受了手术治疗,3例行刮除术,6例行截肢术,12例行切除术。总体而言,3例接受刮除术治疗的患者中有2例出现局部复发,需要进一步手术。局部复发和转移的晚期发生导致10年疾病特异性生存率为93%,到20年时降至39%。
我们未发现OFD进展为釉质细胞瘤的证据。对于OFD和类OFD型釉质细胞瘤患者,观察或刮除等保守治疗通常是成功的。釉质细胞瘤患者需要进行切缘清晰的切除术。晚期肿瘤复发在釉质细胞瘤中并不少见,应考虑延长随访时间。引用本文:2017;99-B:409-16。